Immatics (NASDAQ:IMTX - Get Free Report)'s stock price hit a new 52-week low during trading on Monday . The company traded as low as $5.17 and last traded at $5.21, with a volume of 196987 shares traded. The stock had previously closed at $5.40.
Analysts Set New Price Targets
IMTX has been the topic of a number of analyst reports. Bank of America decreased their target price on shares of Immatics from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, November 19th. The Goldman Sachs Group upgraded shares of Immatics to a "strong-buy" rating in a research report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $16.67.
Check Out Our Latest Report on IMTX
Immatics Price Performance
The stock's 50 day simple moving average is $6.34 and its two-hundred day simple moving average is $8.94. The firm has a market cap of $606.95 million, a P/E ratio of -7.72 and a beta of 0.75.
Institutional Investors Weigh In On Immatics
Institutional investors and hedge funds have recently made changes to their positions in the company. Virtus ETF Advisers LLC increased its position in shares of Immatics by 34.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock valued at $68,000 after acquiring an additional 2,479 shares in the last quarter. Guggenheim Capital LLC bought a new stake in shares of Immatics during the fourth quarter valued at approximately $101,000. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Immatics during the third quarter valued at approximately $114,000. Quarry LP increased its position in shares of Immatics by 29.4% during the third quarter. Quarry LP now owns 11,000 shares of the company's stock valued at $126,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Immatics by 24.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock valued at $163,000 after acquiring an additional 4,477 shares in the last quarter. Institutional investors own 64.41% of the company's stock.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
See Also
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
